New shingles vaccine shows promise in Head-to-Head trial
⭐️ VACCINE ⭐️
Ongoing
This study tests a new shingles vaccine called CRV-101 against the current vaccine, Shingrix, in adults aged 50 and older. The goal is to see if CRV-101 is as safe and triggers a similar immune response. About 1,500 participants will receive either the new vaccine or Shingrix and…
Phase: PHASE2 • Sponsor: Curevo Inc • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:41 UTC